BOLD Earnings — Boundless Bio, Inc. Common Stock Post-ER Performance | BigEarnings
BOLD — Boundless Bio, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$1.44
Market Cap$32.6M
P/E—
52W Range$0.96 – $1.68
Next Earnings2026-08-04
About Boundless Bio, Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
